德乌克拉维西提尼:在第3期斑块性牛皮试验中的实验室参数
April W Armstrong1, Leon Kircik2, Linda Stein Gold3
1Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, 200 Medical Plaza, Suite 450, Los Angeles, CA, 90095, USA. skinstudy@mednet.ucla.com.
Dermatology and therapy
|March 21, 2025
概括
杜克拉维西替尼 (deucravacitinib) 是一种口服的氨酸激酶2抑制剂,在三年内,在斑块性牛皮患者中,实验室参数没有出现临床显著的变化. 与实验室结果相关的不良事件和中止是罕见的.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 德乌克拉维西替尼 (Deucravacitinib) 是一种经批准的口服,选择性,全性氨酸激酶2抑制剂,用于中度至重度的斑块性牛皮.
- 之前的试验 (POETYK PSO-1和PSO-2) 证明了其优于安慰剂和阿普雷米拉斯特的优越性,耐受性良好.
- 本分析重点关注deucravacitinib对POETYK LTE试验中继续治疗的患者实验室参数的长期影响.
研究的目的:
- 评估deucravacitinib对实验室参数在3年时间内的长期影响.
- 评估与deucravacitinib治疗相关的实验室不良事件 (AE) 的发生率和严重程度.
- 为了确定由于实验室AE导致的停产率.
主要方法:
- 分析了52周,第三阶段,双盲POETYK PSO-1和PSO-2试验以及随后的开放标签POETYK LTE试验的数据.
- 患者每天接受6毫克deucravacitinib一次或每天两次服用30毫克apremilast (在初步试验中).
- 从基线对实验室参数,实验室AEs和因实验室AEs而导致的停药的平均变化评估超过3年.
主要成果:
- 在3年内,在1519名暴露于deucravacitinib的患者中,没有观察到临床相关的实验室参数平均变化.
- 实验室AE等级≥3是罕见的,并在3年治疗期间保持稳定.
- 大多数实验室AEs保持在相同的等级,不经常转移到更高的等级 (≤2),并且由于实验室AEs而很少停止.
结论:
- 在3年内,杜克拉维西替尼治疗没有导致实验室参数在临床上有意义的变化.
- 关于实验室参数的安全性概况是有利的,即使与Janus激酶 (JAK) 抑制剂相比.
- 实验室的副作用,包括严重的和停止治疗,是罕见的.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
![Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F3777.jpg&w=3840&q=50)

